Immunovant, Inc.

What Do They Do?

Develops antibody treatments for people with autoimmune diseases driven by harmful antibodies.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

If approved, Immunovant plans to target specialist physicians treating many autoimmune patients through a small U.S. sales organization, and may seek collaborators to support sales in and outside the U.S.

How Are They Changing?

Who Do They Compete With?

Competes with Argenx, Johnson & Johnson, UCB, Viridian Therapeutics, AstraZeneca, Amgen, Sanofi, Dianthus, Crinetics Pharmaceuticals, Lycia Therapeutics, Biohaven, Merida Biosciences, Yarrow Bioscience, Biogen, Merck, and VYNE Therapeutics